Merck & Co., Inc. is projected to achieve an earnings per share of $9.62 in fiscal year 2026, according to new estimates released by Cantor Fitzgerald analyst C. Gould. The research note was issued to investors on June 9th.

Cantor Fitzgerald has reaffirmed its ‘overweight’ rating on Capricor Therapeutics (NASDAQ: CAPR). The brokerage set a $30 price target and estimated FY2025 earnings at $1.71 per share.

Cantor Fitzgerald has reduced its FY2025 earnings per share estimate for MiMedx Group to $0.30. Analyst R. Osborn issued the revised forecast on April 16th, signaling a shift in financial expectations for the NASDAQ-listed company.